Literature DB >> 8379689

Serum free 5-methoxypsoralen fraction in health and psoriasis: relationship with human serum albumin concentration.

P Muret1, P Humbert, S Makki, P Bechtel, S Urien, J P Tillement.   

Abstract

Human serum albumin is known to be the main carrier of 5-methoxypsoralen (5-MOP) in serum. As hypoalbuminaemia may occur in psoriasis with inflammatory syndrome, variability of the free 5-MOP fraction in serum can be expected. The free 5-MOP fraction was determined by equilibrium dialysis in serum samples obtained from 18 psoriatic patients and 18 control subjects. The median free 5-MOP fraction was not significantly different in the psoriatic group (fu = 4.75%) than in the control group (fu = 5%). However, there was a significantly larger variability of the free fraction in the psoriatic group (2.7 to 8.6%) than in the healthy group (3.2 to 6.8%) (p = 0.002). The binding index of 5-MOP (ratio of bound to free concentrations) was correlated with human serum albumin level (r = 0.784). This work confirms that the 5-MOP fraction in human serum is principally serum albumin dependent, as has been described with in vitro models. Free drug monitoring of 5-MOP is discussed.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8379689     DOI: 10.1007/bf00371598

Source DB:  PubMed          Journal:  Arch Dermatol Res        ISSN: 0340-3696            Impact factor:   3.017


  11 in total

1.  Effects of plasma protein binding of drugs on duration and intensity of pharmacological activity.

Authors:  G Levy
Journal:  J Pharm Sci       Date:  1976-08       Impact factor: 3.534

2.  Serum and urine concentrations of 5-methoxypsoralen after oral administration.

Authors:  L M Stolk; W Westerhof; R H Cormane; P A van Zwieten
Journal:  Br J Dermatol       Date:  1981-10       Impact factor: 9.302

3.  Simple equilibrium dialysis-high-performance liquid chromatographic method for the in vitro assessment of 5-methoxypsoralen bound to human albumin.

Authors:  S Makki; P Muret; A Renaud; P Agache; P Magnin
Journal:  J Chromatogr       Date:  1991-02-22

4.  Binding of 5-methoxypsoralen to blood fractions. Influence of albumin and free fatty acids: an in vitro study.

Authors:  P Muret; S Makki; S Urien; P Agache; P Bechtel; J P Tillement
Journal:  Skin Pharmacol       Date:  1993

5.  Reversible binding of 5- and 8-methoxypsoralen to human serum proteins (albumin) and to epidermis in vitro.

Authors:  M Artuc; G Stuettgen; W Schalla; H Schaefer; J Gazith
Journal:  Br J Dermatol       Date:  1979-12       Impact factor: 9.302

6.  A new micronized 5-methoxypsoralen preparation. Higher bioavailability and lower UVA dose requirement.

Authors:  P Treffel; S Makki; P Humbert; H Khaldoun; P Agache
Journal:  Acta Derm Venereol       Date:  1992       Impact factor: 4.437

7.  Pharmacokinetics and pharmacodynamics of psoralens after oral administration: considerations and conclusions.

Authors:  R Brickl; J Schmid; F W Koss
Journal:  Natl Cancer Inst Monogr       Date:  1984-12

8.  Binding of 8-methoxypsoralen to human serum proteins and red blood cells.

Authors:  M Pibouin; R Zini; P Nguyen; A Renouard; J P Tillement
Journal:  Br J Dermatol       Date:  1987-08       Impact factor: 9.302

9.  Role of alpha-1 acid glycoprotein, albumin, and nonesterified fatty acids in serum binding of apazone and warfarin.

Authors:  S Urien; E Albengres; J L Pinquier; J P Tillement
Journal:  Clin Pharmacol Ther       Date:  1986-06       Impact factor: 6.875

10.  5-Methoxypsoralen (Bergapten) in photochemotherapy of psoriasis.

Authors:  H Hönigsmann; E Jaschke; F Gschnait; W Brenner; P Fritsch; K Wolff
Journal:  Br J Dermatol       Date:  1979-10       Impact factor: 9.302

View more
  1 in total

1.  Treatment of psoriasis with a new micronized 5-methoxypsoralen tablet and UVA radiation.

Authors:  F Aubin; S Makki; P Humbert; P Muret; P Agache
Journal:  Arch Dermatol Res       Date:  1994       Impact factor: 3.017

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.